BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Infinity Pharmaceuticals, Inc. (NQ: INFI)
9.940 USD  -0.030 (-0.30%)
Streaming Delayed Price  /  Updated: 4:00 PM EDT, Apr 24, 2014  /  Add to My Watchlist      
(INFI) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
April 24, 2014
(Samurai Trader, 12/13/12)
INFI is a biotech that doesn't have the earnings to have CAN SLIM credentials (it loses money by the truckload), but for some reaason is a very hot stock right now, with a high volume breakout today, from a base that is...(read more)
(Benzinga, 10/11/10)
Over the weekend, Infinity Pharmaceuticals (NASDAQ: INFI) presented initial Phase I data on oral hedgehog inhibitor IPI-926 at the European Society for Medical Oncology meeting in Milan. With i.v. Hsp-90 inhibitor IPI-504 all but dead,...(read more)
(Benzinga, 10/11/10)
Alexza Pharmaceuticals (NASDAQ: ALXA) PDUFA date for AZ-004 is today. Piper expects approval based on two highly positive studies in acute agitation in bipolar and schizophrenic patients, but is cautious about ALXA shares post...(read more)
Infinity Pharmaceuticals (INFI) Company Overview
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here